The pharmacotherapy of chronic pain: A review

Pain Research and Management

Volumn 11, Issue 1, 2006, Pages 11-38

  Lynch, Mary E ^a   Watson, C Peter N ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anticonvulsants; Antidepressants; Cannabinoids; Chronic pain; Opioids; Pharmacotherapy; Topical analgesics

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CELECOXIB; CODEINE; CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; IBUPROFEN; INDOMETACIN; KETOROLAC; LUMIRACOXIB; MELOXICAM; MOBICOX; MORPHINE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXAPROZIN; PARACETAMOL; PENNSAID; PROSTAGLANDIN; PROTON PUMP INHIBITOR; ROFECOXIB; TENOXICAM; UNINDEXED DRUG; VALDECOXIB; WARFARIN;

ABDOMINAL PAIN; AGITATION; ANALGESIA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; APLASTIC ANEMIA; ARTHRITIS; ATAXIA; ATRIOVENTRICULAR BLOCK; BLOOD TOXICITY; BLURRED VISION; CANADA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DELUSION; DEPRESSION; DIABETIC NEUROPATHY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; ENZYME ACTIVITY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GESTATIONAL AGE; HALLUCINATION; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VENTRICLE EXTRASYSTOLE; HEPATITIS; HUMAN; HYPERTENSION; HYPONATREMIA; INFORMATION RETRIEVAL; INSOMNIA; KIDNEY FAILURE; LIVER NECROSIS; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PERMISSIBLE DOSE; MEDICAL LITERATURE; MEDLINE; MEMORY DISORDER; META ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; OPIATE ADDICTION; ORTHOSTATIC HYPOTENSION; OSTEOARTHRITIS; PARESTHESIA; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PROSTAGLANDIN SYNTHESIS; PRURITUS; PUBLICATION; RECEPTOR AFFINITY; RESPIRATION DEPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN ALLERGY; SKIN TOXICITY; SLEEP DISORDER; SOMNOLENCE; STOMACH HEMORRHAGE; STOMACH ULCER; SWEATING; SYSTEMATIC REVIEW; TASTE DISORDER; THORAX PAIN; TREMOR; TRIGEMINUS NEURALGIA; URINE RETENTION; UTERUS CONTRACTILITY; VERTIGO; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 33645748180     PISSN: 12036765     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/642568     Document Type: Review

References (286)

1. Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canada - prevalence, treatment, impact and the role of opioid analgesia. Pain Res Manag 2002;7:179-84.
2. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: A World Health Organization Study in Primary Care. JAMA 1998;280:147-51. (Erratum in 1998;280:1142).
3. Liebeskind JC. Pain can kill. Pain 1991;44:3-4.
4. Page GG. Acute pain and immune impairment. Pain Clin Updates 2005;XIII:1-4.
5. Poobalan AS, Bruce J, King PM, Chambers WA, Krukowski ZH, Smith WC. Chronic pain and quality of life following open inguinal hernia repair. Br J Surg 2001;88:1122-6.
6. Katz J, Jackson M, Kavanagh BP, Sandler AN. Acute pain after thoracic surgery predicts long-term post-thoracotomy pain. Clin J Pain 1996;12:50-5.
7. Canadian Council on Health Services Accreditation Standards Document. 2005, Canadian Council on Health Services Accreditation. p. Standard 13.11.
8. Woolf CJ, Bennett GJ, Doherty M, et al. Towards a mechanism-based classification of pain? Pain 1998;77:227-9.
9. Woolf CJ, Decosterd I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain 1999;(Suppl 6):S141-7.
10. Woolf CJ, Max MB. Mechanism based pain diagnosis: Issues for analgesic drug development. Anesthesiology 2001;95:241-9.
11. Griffin RS, Woolf CJ. Pharmacology of analgesia. In: Golan DE, ed. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Philadelphia: Lippincott, Williams and Wilkins, 2005:229-43.
12. Wall PD. Introduction to the edition after this one. In: Wall PD, Melzack R, eds. The Textbook of Pain, 3rd edn. London: Churchill Livingstone, 1994:1-7.
13. Dworkin RH. An overview of neuropathic pain: Syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002;18:343-9.
14. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34.
15. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994;59:9-43.
16. Cashman JN. The mechanisms of action of NSAIDS in analgesia. Drugs 1996;52:13-23.
17. Malmberg AB, Yaksh TL. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther 1992;263:136-46.
18. Malmberg AB, Yaksh TL. Pharmacology of the spinal action of ketorolac, morphine, ST-91, U50488H, and L-PIA on the formalin test and an isobolographic analysis of the NSAID interaction. Anesthesiology 1993;79:270-81.
19. Yaksh TL, Dirig DM, Malmberg AB. Mechanism of action of nonsteroidal anti-inflammatory drugs. Cancer Invest 1998;16:509-27.
20. Wallace JL, Cirino G. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 1994;15:405-6.
21. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
22. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: Implications for nonsteroidal anti-inflammatory drug therapy. Semin Arthritis Rheum 1996;26:435-46.
23. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cycloocygenase inhibition. Science 1992;257:1278-9.
24. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
25. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 2004;364:665-74.
26. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
27. Tannenbaum H, Bombardier C, Davis P, Russell AS. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-57.
28. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: A population study in elderly adults. Ann Intern Med 2005;142:481-9.
29. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005;365:475-81.
30. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157-64.
31. Baumann TJ. Pain management. In: Piro JT, Talbert RL, Hayes PE, Yee GC, Matzke GR, Posey LM, eds. Pharmacotherapy. A Pathophysiologic Approach, 5th edn. New York: McGraw Hill, 2002:1107.
32. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
33. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: A new model applied to chronic NSAID use. Pain 2000;85:169-82.
34. Singh G, Ramey DR, Morfeld D, Fries JF. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther 1994;62:175-91.
35. Lipani J, Poland M. Clinical update of the relative safety of nabumetone in long term trials. Inflammopharmacology 1995;3:351-6.
36. Sunshine A, Olsen NZ. Nonnarcotic analgesics. In: Wall PD, Melzack R, eds. Textbook of Pain, 3rd edn. United Kingdom: Churchill Livingstone, 1994:923-42.
37. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926-31.
38. Pelissier T, Alloui A, Caussade F, et al. Paracetamol exerts a spinal antinociceptive effect involving an indirect interaction with 5-hydroxytryptamine3 receptors: In vivo and in vitro evidence. J Pharmacol Exp Ther 1996;278:8-14.
39. Bonnefont J, Alloui A, Chapuy E, Clottes E, Eschalier A. Orally administered paracetamol does not act locally in the rat formalin test: Evidence for a supraspinal, serotonin-dependent antinociceptive mechanism. Anesthesiology 2003;99:976-81.
40. Bonnefont J, Courade JP, Alloui A, Eschalier A. [Antinociceptive mechanism of action of paracetamol]. Drugs 2003;63:1-4.
41. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982;32:671-3.
42. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-34.
43. Lynch ME. Antidepressants as analgesics. A review of random controlled trials examining analgesic effects of antidepressant agents. J Psychiatry Neurosci 2001;26:30-6.
44. Max MB. Antidepressants as analgesics. In: Progress in Pain Research Management. HL Fields, JC Liebeskind, eds. Seattle: IASP Press, 1994:229-46.
45. Max MB. Thirteen consecutive well-designed randomized trials show that anti-depressants reduce pain in diabetic neuropathy and postherpetic neuralgia. Pain Forum 1995;4:248-53.
46. McQuay HJ, Moore RA. Antidepressants and chronic pain. BMJ 1997;314:763-4.
47. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217-27.
48. Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998;51:1682-8.
49. Cardenas DD, Warms CA, Turner JA, Marshall H, Brooke MM, Loeser JD. Efficacy of amitriptyline for relief of pain in spinal cord injury: Results of a randomized controlled trial. Pain 2002;96:365-73.
50. Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 2002;98:195-203.
51. Onghena P, Van Houdenhov B. Antidepressant-induced analgesia in chronic nonmalignant pain: A meta-analysis of 39 placebo controlled studies. Pain 1992;49:205-19.
52. Eschalier A, Ardid D, Dubray C. Tricyclic and other antidepressants as analgesics. In: Sawnyok J, Cowan A, eds. Novel Aspects of Pain Management: Opioids and Beyond. New York: Wiley, 1999:303-20.
53. Pancrazio JJ, Kamatchi GL, Roscoe AK, Lynch C III. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther 1998;284:208-14.
54. Song JH, Ham SS, Shin YK, Lee CS. Amitriptyline modulation of Na(+) channels in rat dorsal root ganglion neurons. Eur J Pharmacol 2000;401:297-305.
55. Lavoie PA, Beauchamp G, Elie R. Tricyclic antidepressants inhibit voltage-dependent calcium channels and Na+-Ca2+ exchange in rat brain cortex synaptosomes. Can J Physiol Pharmacol 1994;68:1414-8.
56. Gerner P, Mujtaba M, Sinnott CJ, Wang GK. Amitriptyline versus bupivacaine in rat sciatic nerve blockade. Anesthesiology 2001;94:661-7.
57. Khan MA, Gerner P, Want GK. Amitriptyline for prolonged cutaneous analgesia in the rat. Anesthesiology 2002;96:109-16.
58. Eisenach JC, Gebhart GF. Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Anesthesiology 1995;83:1046-53.
59. Esser MJ, Sawynok J. Caffeine blockade of the thermal anti-hyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. Eur J Pharmacol 2000;399:131-9.
60. Sierralta F, Pinardi G, Mendez M, Miranda HF. Interaction of opioids with antidepressant-induced antinociception. Psychopharmacology (Berl) 1995;122:374-8.
61. Ulugol A, Karadag HC, Tamer M, Firat Z, Aslantas A, Dokmeci I. Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci Lett 2002;328:129-32.
62. Esser MJ, Sawnyok J. Caffeine blockade of the thermal anti-hyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. Eur J Pharmacol 2000;399:131-9.
63. Esser MJ, Chase T, Allen GV, Sawynok J. Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: Multiple interactions. Eur J Pharmacol 2001;430:211-8.
64. Galeotti N, Ghelardini C, Capaccioli S, Quattrone A, Nicolin A, Bartolini A. Blockade of clomipramine and amitriptyline analgesia by an antisense oligonucleotide to mKv1.1, a mouse Shaker-like K+ channel. Eur J Pharmacol 1997;330:15-25.
65. Galeotti N, Ghelardini C, Bartolini A. Involvement of potassium channels in amitriptyline and clomipramine analgesia. Neuropharmacology 2001;40:75-84.
66. Sawynok J. Topical and periphally acting analgesics. Pharm Rev 2003;55:1-20.
67. Sawynok J, Esser MJ, Reid AR. Antidepressants as analgesics: An overview of central and peripheral mechanisms of action. J Psychiatry Neurosci 2001;26:21-9.
68. Sindrup SH, et al. Concentration response relationship in imipramine treatment of diabetic symptoms. Clin Pharmacol Ther 1990;47:509-15.
69. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-91.
70. Markowitz JS, Patrick KS. Venlafaxine-tramadol similarities. Med Hypotheses 1998;51:167-8.
71. Galer BS. Neuropathic pain of peripheral origin: Advances in pharmacologic treatment. Neurology 1995;45(Suppl 9):S17-25.
72. Songer DA, Schule H. Venlafaxine for the treatment of chronic pain. Am J Psychiatry 1996;153:737.
73. Sumptom JE, Moulin DE. Treatment of neuropathic pain with venalfaxine. Ann Pharmacother 2001;35:557-9.
74. Taylor K, Rowbotham MC. Venlafaxine hydrochloride and chronic pain. West J Med 1996;165:147-8.
75. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Pain 2004;110:697-706. (Erratum in 2005;113:248).
76. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial. Neurology 2003;60:1284-9.
77. Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002;6:17-24.
78. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84.
79. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18.
80. Wernicke JF. Duloxetine in treatment of diabetic neuropathic pain. Pharmacotherapy 2004;24:1422. (Abst)
81. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53.
82. Jung AC, Staiger T, Sullivan M. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med 1997;12:384-9.
83. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6.
84. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-44.
85. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-52.
86. Bendtsen L, Jensen R, Olesen J. A nonselective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension type headache. Neurol Neurosurg Psychiatry 1996;61:285-90.
87. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000;55:915-20.
88. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: A quantitative systematic review. J Pain Symptom Manag 2000;20:449-559.
89. Gallagher RM, Verma S. Mood and anxiety disorders in chronic pain. In: Dworkin RH, Breitbart WS, eds. Psychosocial Aspects of Pain: A Handbook for Healthcare Providers, Progress in Pain Research and Management, Vol 27. Seattle: IASP Press, 2004:139-78.
90. Semenchuk MR, Sherman S, Davis B. Double blind randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001;57:1583-8.
91. Mulrow CD, Williams JW Jr, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care practices. Am J Med 2000;108:54-64.
92. Thase ME. Evaluating Antidepressants therapies: Remission as the optimum outcome. J Clin Psychiatry 2003;64:18-25.
93. Backonja M. Neuromodulating drugs for the symptomatic treatment of neuropathic pain. Curr Pain Headache Rep 2004;8:212-6.
94. Berde CB. New and old anticonvulsants for management of pain. IASP Newsletter Technical Corner January/February 1997:3-5.
95. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004;10:685-92.
96. Rice ASC, Maton S, NPS Group. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain 2001;94:215-24.
97. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998;280:1837-42.
98. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double blind study comparing efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999;159:1931-7.
99. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998;280:1831-6.
100. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: A placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999;66:251-2.
101. Serpell MG, NPS Group. Gabapentin in neuropathic pain syndromes: A randomised, double blind, placebo-controlled trial. Pain 2002;99:557-66.
102. Levendoglu F, Ogun CO, Ozerbil O, Ogun TC, Ugurlu H. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 2004;29:743-51.
103. Spira PJ, Beran RG; Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: A randomized, placebo-controtled study. Neurology 2003;61:1753-9.
104. Bridges D, Thompson SWN, Rice ASC. Mechanisms of neuropathic pain. Br J Aneasth 2001;87:12-26.
105. Frampton JE, Foster RH. Pregabalin in the treatment of postherpetic neuralgia. Drugs 2005;65:111-8.
106. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2003;60:1274-83.
107. Sabatowski R, Galvez R, Cherry DA, et al; 1008-045 Study Group. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomized, placebo-controlled clinical trial. Pain 2004;109:26-35.
108. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain 2005;6:253-260.
109. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004;63:2104-10.
110. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 2004;110:628-38.
111. Randinitis EJ, Posvar EL, Alvey CW. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003;43:277-83.
112. Rowbotham M, Young J, Sharma U, et al. Pregabalin shows reduction in pain by day three of treatment. J Pain 2003;4(Suppl 1):63.
113. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: A systematic review. BMJ 1995;311:1047-52.
114. Backonja M, Serra J. Pharmacologic management part 1: Better-studied neuropathic pain diseases. Pain Med 2004;5:S28-S47.
115. Watson CPN. Management issues of neuropathic trigeminal pain from a medical perspective. J Orofac Pain 2004;18:366-73.
116. Portenoy RK. Drug therapy for neuropathic pain. Drug Therapy 1993;23:41-53.
117. Guay DP. Oxcarbazepine, topiramate, zonisamide, and levetiracetam: Potential use in neuropathic pain. Am J Geriatr Pharmacother 2003;1:18-37.
118. Eisenberg E, Alon N, et al. Lamotrigine in the treatment of painful diabetic neuropathy. Abstracts 8th World Congress on Pain. Seattle: IASP Press, 1996:372.
119. McCleane G. Lamotrigine in the management of neuropathic pain: A review of the literature. Clin J Pain 2000;16:321-6.
120. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (lamictal) in refractory trigeminal neuralgia: Results from a double-blind placebo controlled crossover trial. Pain 1997;73:223-30.
121. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study. Neurology 2001;57:505-9.
122. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: A randomized controlled trial. Neurology 2001;56:184-90.
123. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: A randomized controlled trial. Pain 2002;96:375-83.
124. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000;54:2115-9.
125. McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: A randomized, double-blind, placebo controlled trial. Pain 1999;83:105-7.
126. Lunardi G, Leandri M, Albano C, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology 1997;48:1714-7.
127. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain 2003;19:59-68.
128. McGeeney BE. Topiramate in the treatment of cluster headache. Curr Pain Headache Rep 2003;7:135-8.
129. Gilron I, Booher SL, Rowan JS, Max MB. Topiramate in trigeminal neuralgia: A randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol 2001;24:109-12.
130. Edwards KR, Glanz MJ. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Neurology 2000;54:A81.
131. Thienel U, Neto W, Schwabe SK, Vijapurkar U; Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: Findings from three double-blind placebo controlled trials. Acta Anaesthesiol Scand 2004;110:221-31.
132. Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: A randomised double-blind versus placebo study. Neurol Sci 2004;25:245-50.
133. Brandes JL, Saper JR, Diamond M, et al; MIGR-002 Study Group. Topiramate for migraine prevention: A randomized controlled trial. JAMA 2004;291:965-73.
134. Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol 2004;61:490-5.
135. Diener HC, Tfelt-Hansen P, Dahlof C, et al; MIGR-003 Study Group. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with proplanalol as an active control. J Neurol 2004;251:943-50.
136. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23:820-4.
137. Storey JR, Calder CS, Hart DE, Potter DL.. Topiramate in migraine prevention: A double-blind placebo-controlled study. Headache 2001;41:968-75.
138. Edwards KR, Potter DL, Wu SC, Kamin M, Hulihan J. Topiramate in the preventive treatment of episodic migraine: A combined analysis from pilot, double-blind, placebo-controllled trials. CNS Spectr 2003;8:428-32.
139. McQuay HJ. Neuropathic pain: Evidence matters. Eur J Pain 2002;6:11-8.
140. Arkinstall W, Sandler A, Goughnour B, Babul N, Harsanyi Z, Darke AC. Efficacy of controlled release codeine in chronic non-malignant pain: A randomized, placebo-controlled clinical trial. Pain 1995;62:169-78.
141. Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996;347:143-7.
142. Harati Y, Gooch C, Swenson M, et al. Double blind randomized trial of tramadol for the treatment of pain of diabetic neuropathy. Neurology 1998;50:1842-6.
143. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain, a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
144. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26:862-9.
145. Peloso PM, Bellamy N, Bensen W, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip and knee. J Rheumatol 2000;27:764-71.
146. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock controlled-release oxycodone therapy for osteoarthritis-related pain: Placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853-60.
147. Huse E, Larbig W, Flor H, Birbaumer N. The effect of opioids on phantom limb pain and cortical reorgnization. Pain 2001;90:47-55.
148. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebo-controlled, double-blind trial and open label extension trial. J Pain Symptom Manage 2002;23:278-91.
149. Maier C, Hildebrandt J, Klinger R, Henrich-Eberl C, Lindena G; MONTAS Study Group. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain - results of a double-blind, placebo-controlled trial (MONTAS). Pain 2002;97:223-33.
150. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59:1015-21.
151. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-8.
152. Jovey RD, Ennis J, Gardner-Nix J, et al; Canadian Pain Society. Use of opioid analgesics for the treatment of chronic noncancer pain - A consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manage 2003;8(Suppl A):3A-28A.
153. Schumacher HE, Basbaum AI, Way WL. Opioid analgesics and antagonists. In: Katzung BG, ed. Basic and Clinical Pharmacology, 9th edn. New York: Lange Medical Books, McGraw-Hill, 2004:497-518.
154. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995;332:1685-90.
155. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996;335:1124-32.
156. Williams DG, Hatch DJ, Howard RF. Codeine phosphate in paediatric medicine. Br J Anaesth 2001;86:413-21.
157. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988;2:914-5.
158. Chen ZR, Somogyi AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and weven extensive metabolizers. Br J Clin Pharmacol 1991;31:381-90.
159. Lipkowski AW, Carr DB. Rethinking opioid equivalence. Pain Clinical Updates 2002;X:1-4.
160. Wolff K, Rostami-Hodjegan A, Shires S, et al. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol 1997;44:325-34.
161. Pasternak G. Multiple morphine and enkephalin receptors and the relief of pain. JAMA 1988;259:1362-7.
162. Pasternak G. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 2001;22:67-70.
163. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995;187:165-8.
164. Davis A, Inturrisi C. d-methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharm Exp Ther 1999;289:1048-53.
165. Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: Structural determinants and role in antinociception. J Pharm Exp Ther 1995;274:1263-9.
166. Callahan RJ, Au JD, Paul M, Liu C, Yost CS. Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes; stereospecific and subunit effects. Anesth Analg 2004;98:653-9.
167. Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H. Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Biochem Pharmacol 1998;56:553-9.
168. Gorman A, Elliott K, Inturrisi C. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat brain and spinal cord. Neurosci Lett 1997;223:5-8.
169. Gagnon B, Almahrezi A. Methadone in the treatment of neuropathic pain. Pain Res Manage 2003;8:149-54.
170. Moulin D. Use of methadone for neuropathic pain. Pain Res Manage 2003;8:131-2.
171. Bruera E, Sweeney C. Methadone use in cancer patients with pain. J Palliative Med 2002;5:127-37.
172. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997;70:109-15.
173. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: A review. Pain 1993;52:137-47.
174. Davis M, Walsh D. Methadone for the relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001;9:73-83.
175. Altier N, Dion D, Boulanger A, Choiniere M. Successful use of methadone in the treatment of chronic neuropathic pain arising from burn injuries: A case study. Burns 2001;27:771-5.
176. Gagnon B, Bruera E. Differences in ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manag 1999;18:120-4.
177. Hays H, Woodroffe M. Use of methadone in treating chronic noncancer pain. Pain Res Manage 1998;4:23-7.
178. Lynch ME. A review of the use of methadone for treatment of chronic non-cancer pain. Pain Res Manage 2005;10:133-44.
179. Mullican WS, Lacy JR; ftT-A-S Group. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: A comparative trial. Clin Ther 2001;23:1429-45.
180. Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol 2000;27:772-8.
181. Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M; Protocol CAPSS-112 Study Group. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: A multicenter, randomized, double blind, placebo-controlled outpatient study. Clin Ther 2003;23:1123-40.
182. Wilder-Smith CH, Hill L, Spargo K, Kalla A. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAIDS: A randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001;91:23-31.
183. Babul N, Noveck R, Chipman H, Roth SH, Gana T, Albert K. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: A randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manag 2004;28:59-71.
184. Budd K. Chronic pain-challenge and response. Drugs 1994;47(Suppl 1):33-8.
185. Abramowicz M. Tramadol - A new oral analgesic. In: Abamowicz M, ed. The Medical Letter, vol 37. 1995:59-60.
186. Twycross RG. Opioids. In: Melzack R, Wall PD, eds. Textbook of Pain. London: Churchill Livingstone, 1994;943-62.
187. Barnung SK, Treschow M, Borgbjerg FM. Respiratory depression following oral tramadol in a patient with impaired renal function. Pain 1997;71:111-2.
188. Savage SR. Assessment for addiction in pain treatment settings. Clin J Pain 2002;18:S28-S38.
189. Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: Evolution towards universal agreement. J Pain Symptom Manag 2003;26:655-67.
190. Kirsh KL, Whitcomb LA, Donaghy K, Passik SD. Abuse and addiction issues in medically ill patients with pain; Attempts at clarification of terms and empirical study. Clin J Pain 2002;18:S52-S60.
191. Weaver M, Schnoll S. Abuse liability in opioid therapy for pain treatment in patients with an addiction history. Clin J Pain 2002;18:S61-S69.
192. Lindstrom P, Lindbolm U. The analgesic effect of tocainide in trigeminal neuralgia. Pain 1987;28:45-50.
193. Jarvis B, Coukell AJ. Mexiletine: A review of it's therapeutic use in painful diabetic neuropathy. Drugs 1998;56:691-707.
194. Dejgard A, Peterson P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988;1:9-11.
195. Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992;15:1550-5.
196. Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care 1997;20:1594-7.
197. Wright J, Oki JM, Graves L. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother 1997;31:29-34.
198. Wallace MS, Magnuson S, Ridgeway B. Efficacy of oral mexiletine for neuropathic pain with allodynia: A double-blind, placebo-controlled, crossover study. Reg Anesth Pain Med 2000;25:459-67.
199. Chabal C, Jacobson L, Mariano A, Chaney E, Britell CW. The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiology 1992;76:513-7.
200. Kemper CA, Kent G, Burton S, Deresinski SC. Mexiletine for HIV-infected patients with painful peripheral neuropathy: A double-blind, placebo-controlled, cross over trial. J Acquir Immune Defic Syndr Human Retrovirol 1998;19:367-72.
201. Chiou-Tan FY, Tuel SM, Johnson JC, Priebe MM, Hirsh DD, Strayer JR. Effect of mexiletine on spinal cord injury dysesthetic pain. Am J Phys Med Rehabil 1996;75:84-7.
202. Fassoulaki A, Patris K, Sarantopoulos C, Hogan Q. The analgesic effect of gabapentin and mexiletine after breast surgery for cancer. Anesth Analg 2002;95:985-91.
203. Fassoulaki A, Sarantopoulos C, Melemeni A, Hogan Q. Regional block and mexiletine: The effect on pain after cancer breast surgery. Reg Anesth Pain Med 2001;26:223-8.
204. Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine. J Pain Symptom Manage 1996;12:161-7.
205. Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 2004;62:218-25.
206. Lechin F, van der Dijs B, Lechin M. Pimozide therapy for trigeminal neuralgia. Arch Neurol 1989;46:960-3.
207. Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000;16:188-92.
208. Eisenach JC, De Kock M, Klimscha W. Alpha 2-adrenergic agonists for regional anesthesia: A clinical review of clonidine (1984-1995). Anesthesiology 1996;85:655-74.
209. Glynn C, O'Sullivan K. A double blind randomized comparison of the effects of epidural clonidine, lignocaine and the combination of clonidine and lignocaine in patients with chronic pain. Pain 1995;64:337-43.
210. Rauck RL, Eisenach JC, Jackson K, Young LD, Southern J. Epidural clonidine treatment for refractory RSD. Anesthesiology 1993;79:1163-9.
211. Eisenach JC, Rauck RL, Buzzanell C. Epidural clonidine analgesia for intractable cancer pain: Phase 1. Anesthesiology 1989;71:647-52.
212. Glynn C, O'Sullivan K. A double blind randomised comparison of the effects of epidural clonidine, lignocaine and a combination of clonidine and lignocaine in patients with chronic pain. Pain 1996;64:337-43.
213. Glynn C, Dawson D, Sanders R. A double-blind comparison between epidural morphine and epidural clonidine in patients with chronic non-cancer pain. Pain 1988;34:123-8.
214. Carroll D, Jadad A, King V, Wiffen P, Glynn C, McQuay H. Single-dose, randomized, double-blind, double-dummy cross-over comparison of extradural and I.v. clonidine in chronic pain. Br J Anesth 1993;71:665-9.
215. Zeigler D, Lynch SA, Muir J, Benjamin J, Max MB. Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 1992;48:403-8.
216. Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. Pain 1995;60:267-74.
217. Krames E. Implantable devices for pain control: Spinal cord stimulation and intrathecal therapies. Best Pract Res Clin Anaesthesiol 2002;16:619-45.
218. Slonimski M, Abram SE, Zuniga RE. Intrathecal baclofen in pain management. Reg Anesth Pain Med 2004;29:269-76.
219. Bowery NG, Malcangio M. a-Aminobutyric acid and pain. In: Sawynok JA, ed. Novel Aspects of Pain Management: Opioids and Beyond. Mississauga: Wiley-Liss Inc, 1999:249-64.
220. Fromm GH. Baclofen as an adjuvant analgesic. J Pain Symptom Manag 1994;9:500-9.
221. Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: A double blind study and long-term follow-up. Ann Neurol 1984;15:240-4.
222. Herman RM, Luzansky SC, Ippolito R. Intrathecal baclofen suppresses centralpain in patients with spinal lesions, a pilot study. Clin J Pain 1992;8:338-45.
223. Tiara T, Kanamura H, Tanikawa T. A new approach to control central deafferentation pain: Spinal intrathecal baclofen. Stereotactic and Functional Neurosurgery 1995;65:101-5.
224. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58.
225. Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain 2005;115:1-4.
226. Tietjen GE. The risk of stroke in patients with migraine and implications for migraine management. CNS Drugs 2005;19:683-92.
227. Wenzel RG, Sarvis CA, Krause ML. Over-the-counter drugs for acute migraine attacks: Literature review and recommendations. Pharmacotherapy 2003;23:494-505.
228. Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN. Aspirin is efficacious for treatment of acute migraine. Headache 2005;45:283-92.
229. Holroyd KA, Penzien DB, Cordingley GE. Propranalol in the management of recurrent migraine: A meta-analytic review. Headache 1991;31:333-40.
230. Chronicle E, Mulleners CE. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004;3:CD003226.
231. Schmidt R, Oestreich W. Flunarizine in migraine prophylaxis: the clinical experience. J Cardiovasc Pharmacol 1991;18:S21-6.
232. Leone M, Grazzi L, La Mantia L, Bussone G. Flunarizine in migraine: A minireview. Headache 1991;31:388-91.
233. Tomkins GE, Jackson JL, O'Malley PG, Balden E, Santoro JE. Treatment of chronic headache with antidepressants: A meta-analysis. Am J Med 2001;111:54-63.
234. Holroyd KA, Penzien DB. Pharmacological versus non-pharmacological prophylaxis of recurrent migraine headache: A meta-analytic review of clinical trials. Pain 1990;42:1-13.
235. Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: A randomized controlled trial. CMAJ 2004;171:333-8.
236. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: A randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 2004;164:2017-23.
237. Tugwell PS, WG A, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. J Rheumatol 2004;31:2002-12.
238. Watson CPN. Topical capsaicin as an adjuvant analgesic. J Pain Symptom Manag 1994;9:425-33.
239. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: Double-blind placebo controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44.
240. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: Results of a randomized, double blind, vehicle controlled, 3 week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002;18:297-301.
241. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch:Results of an enriched enrollment study. Pain 1999;80:533-8.
242. McCleane G. Topical application of doxepin hydrochloride can reduce the symptoms of complex regional pain syndrome: A case report. Injury Int J Care Injured 2002;33:88-9.
243. McCleane GJ. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: A randomized, double blind, placebo-controlled study. Br J Clin Pharmacol 2000;49:574-9.
244. McCleane GJ. Topical doxepin hydrochloride reduces neuropathic pain: A randomized, double-blind placebo controlled study. The Pain Clinic 2000;12:47-50.
245. Lockhart E. Topical combination of amitriptyline and ketamine for post herpetic neuralgia. J Pain 2004;5(S1):82.
246. Lynch ME, Clark AJ, Sawnyok J. Topical amitriptyline, ketamine and a combination of both in the treatment of neuropathic pain. Clin J Pain 2003;19:323-7.
247. Moore RA, Tramer MR, Carroll D, Wiffen PJ, McQuay HJ. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998;316:333-8.
248. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases. Drugs 2000;2000:555-74.
249. Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions. Drugs 1998;56:783-99.
250. Mason L, Moore RA, Edwards JE, McQuay HJ, Derry S, Wiffen PJ. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ 2004;328:995.
251. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004;328:991.
252. Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 1994;46:517-22.
253. Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J Pain 2005;6:644-9.
254. Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical amitriptyline 2% and ketamine 1% in neuropathic pain syndromes: A randomized double blind placebo controlled trial. Anesthesiology 2005;103:140-6.
255. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995;37:246-53.
256. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: A randomized, double-blind, placebo-controlled study. Pain 2003;106:151-8.
257. Watson CP. Topical agents for neuropathic pain: A systematic review. In: Merskey J, Loeser JD, Dubner R, eds. The Paths of Pain 1975-2005. Seattle: IASP Press, 2005:483-501.
258. Rice ASC. Cannabinoids and pain. Curr Opin Invest Drugs 2001;2:399-413.
259. Lynch ME. Preclinical science regarding cannabinoids as analgesics: An overview. Pain Res Manag 2005;10(Suppl A):7A-14A.
260. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobio 2001;63:569-609.
261. Walker JM, Strangman NM, Huang SM. Cannabinoids and pain. Pain Res Manage 2001;6:74-9.
262. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2002;323:1-6.
263. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004.
264. Notcutt WG, Price M, Chapman G. Clinical experience with nabilone for chronic pain. Pharm Sci 1997;3:551-5.
265. Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995;345:579.
266. Zajicek J, Fox P, Sanders H, et al; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26.
267. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76:1664-9.
268. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain 2004;112:299-306.
269. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-9.
270. Clark AJ, Lynch ME, Ware M, Beaulieu P, McGilveray IJ, Gourlay D. Guidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manag 2005;10(Suppl A):44A-6A.
271. Clark AJ, Lynch ME. Cannabinoids for pain management - what is their role? Pain Res Manage 2005;10(Suppl A):5A-6A.
272. Ware M, Beaulieu P. Cannabinoids for the treatment of pain: An update on recent clinical trials. Pain Res Manage 2005;10(Suppl A):27A-30A.
273. Ware M, Tawfik VL. Safety issues concerning the medical use of cannabis and cannabinoids. Pain Res Manage 2005;10(Suppl A):31A-7A.
274. Beaulieu P. Toxic effects of cannabis and cannabinoids: Animal data. Pain Res Manage 2005;10(Suppl A):23A-6A.
275. McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manage 2005;10(Suppl A):15A-22A.
276. Gourlay D. Addiction and pain medicine. Pain Res Manage 2005;10(Suppl A):38A-43A
277. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004;62:2098-100.
278. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: Results of a prospective survey. Pain 2003;102:211-6.
279. Ogborne AC, Smart AC. Cannabis users in the general Canadian population. Subst Use Misuse 2000;35:301-11.
280. Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 2003;30:201-5.
281. Merskey H, Bogduk N, eds. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Terms. Seattle: IASP Press, 1994.
282. Simpson DM, McArthur JC, Olney R, et al; Lamotrigine HIV Neuropathy Study Team. Lamotrigine for HIV-associated painful sensory neuropathies: A placebo controlled trial. Neurology 2003;60:1508-14.
283. Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J. A treatment algorithm for neuropathic pain. Clin Ther 2004;26:951-79. (Erratum in 2004;26:2163).
284. Coambs RB, Jarry JL, Santhiapillai ac, Abrahamsohn RV, Atance CM. The SISAP: A new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain in general medical practice. Pain Res Manage 1996;1:155-62.
285. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa: Canadian Pharmacists Association, 2005:1471-3.
286. Bezchlibnyk-Butler KZ, Jeffries JJ, eds. Clinical Handbook of Psychotropic Drugs, 15th edn. Cambridge: Hogrefe and Huber, 2005:44-5.